All In Biotech

Drug Trial Radar · NCT07101445

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Prevent Allergic Reactions to Aphexda With Dexamethasone (PARADE)

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

94

Planned (sponsor's estimate)

Start

Sep 24, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Emory UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI); Gamida Cell ltd
First posted
Aug 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase IV trial compares the effect of premedication regimens with methylprednisolone versus dexamethasone for the prevention of allergic reaction to motixafortide in patients with multiple myeloma (MM) undergoing stem cell mobilization. MM patients that receive an autologous stem cell transplantation (ASCT) have better outcomes. However, not all MM patients are able to have a successful stem cell mobilization and collection which is needed to proceed to ASCT. The addition of motixafortide prior to stem cell mobilization has allowed more MM patients to collect the needed number of stem cells to proceed to ASCT. However, motixafortide does produce systemic and injection site reactions in many patients. The optimal medication regimen to prevent reactions remains unknown. A premedication regimen with dexamethasone prior to motixafortide decreases the incidence of reactions in many patients and is considered the standard of care regimen for the prevention of systemic and injection site reactions to motixafortide in patients with MM undergoing stem cell mobilization. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen side effects/allergic reactions. However, dexamethasone is associated with other side effects like headache, difficulty sleeping, high blood glucose, high blood pressure, mood changes, fluid retention, and infection, among others. A premedication regimen with methylprednisolone prior to motixafortide may work better to decrease the incidence of reactions to motixafortide in patients with MM undergoing stem cell mobilization. Methylprednisolone is in a class of medications called corticosteroids. It works to decrease side effects/allergic reactions by changing the way the immune system works. Giving methylprednisolone may be safe, tolerable and/or more effective than dexamethasone as part of a premedication regimen for the prevention of allergic reaction to motixafortide in patients with MM undergoing stem cell mobilization.

Conditions

  • Multiple Myeloma

Interventions

  • AcetaminophenDrug

    Given by mouth (PO).

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • DexamethasoneDrug

    Given intravenously (IV).

  • Electronic Health Record ReviewOther

    Ancillary studies

  • FamotidineDrug

    Given by mouth (PO).

  • LoratadineDrug

    Given by mouth (PO).

  • MethylprednisoloneDrug

    Given intravenously (IV).

  • MontelukastDrug

    Given by mouth (PO).

  • MotixafortideDrug

    Given subcutaneously (SC).

  • PheresisProcedure

    Undergo apheresis

  • Questionnaire AdministrationOther

    Ancillary studies

  • Recombinant Granulocyte Colony-Stimulating FactorBiological

    Give Granulocyte Colony-Stimulating Factor (G-CSF).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of systemic reactionsTime frame: At day 4 and 5
  2. Incidence and severity of injection site reactionsTime frame: At day 4 and 5

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.